Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
Astolfi L, Ghiselli S, Guaran V, et al. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. Oncol Rep 2013; 29(4): 1285-92.
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol 2010; 42(1): 40-3.
Sumiyoshi M, Soda H, Sadanaga N, et al. Alert regarding cisplatin-induced severe adverse events in cancer patients with xeroderma pigmentosum. Intern Med 2017; 56(8): 979-82.
Pujol J-L, Lafontaine T, Quantin X, et al. Neoadjuvant Etoposide, Ifosfamide, and Cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Chest 1999; 115(1): 144-50.
Otty Z, Skinner MB, Dass J, et al. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia Pac J Clin Oncol 7(3): 287-92.
Felix HC, Seaberg B, Bursac Z, Thostenson J, Stewart MK. Why do patients keep coming back? results of a readmitted patient survey. Soc Work Health Care 2015; 54(1): 1-15.
Bell JF, Whitney RL, Reed SC, et al. Systematic review of hospital readmissions among patients with cancer in the United States. Oncol Nurs Forum 2017; 44(2): 176-91.
Donzé J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in patients with common comorbidities: Retrospective cohort study. BMJ 2013; 347.
Ji H, Abushomar H, Chen X-K, Qian C, Gerson D. All-cause readmission to acute care for cancer patients. Healthc Q 2012; 15(3): 14-6.
El Morabet N, Uitvlugt EB, van den Bemt BJF, van den Bemt PMLA, Janssen MJA, Karapinar-Çarkit F. Prevalence and preventability of drug-related hospital readmissions: A systematic review. J Am Geriatr Soc 2018; 66(3): 602-8.
Steventon A, Billings J. Preventing hospital readmissions: The importance of considering ‘impactibility,’ not just predicted risk. BMJ Qual Amp Saf 2017; 26(10): 782.
Brana I, Siu LL. Locally advanced head and neck squamous cell cancer: Treatment choice based on risk factors and optimizing drug prescription. Ann Oncol 2012; 23(10): x178-85.
Brown E, Burgess D, Li C, Canter R, Bold R. Hospital readmissions: Necessary evil or preventable target for quality improvement. Ann Surg 2014; 260(4): 583-91.
Shapiro JS, Humeniuk MS, Siddiqui MA, Bonthu N, Schroeder DR, Kashiwagi DT. Risk factors for readmission in patients with cancer comanaged by hospitalists. Am J Med Qual 2017; 32(5): 526-31.
Solomon R, Egorova N, Franco R, Bickell NA. Thirty-day readmissions in metastatic cancer patients: Room for improvement? J Clin Oncol 2017; 35(15): 6541.
Epstein AS, Crosbie C, Martin SC, et al. 30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: Characteristics and preventability. Hosp Pract 2014; 42(5): 34-44.
Ghiam MK, Langerman A, Sargi Z, Rohde S. Head and neck cancer patients: Rates, reasons, and risk factors for 30-day unplanned readmission. Otolaryngol Head Neck Surg 2018; 159(1): 149-57.
González JR, Fernandez E, Moreno V, et al. Sex differences in hospital readmission among colorectal cancer patients. J Epidemiol Community Health 2005; 59(6): 506.
Chang H-T, Chen C-K, Lin M-H, Chou P, Chen T-J, Hwang S-J. Readmissions in cancer patients after receiving inpatient palliative care in Taiwan: A 9-Year Nationwide population-based cohort study. Medicine (Baltimore) 2016; 95(8): e2782.
Sebastian MR, Hergenroeder A. Does rate of weight gain during hospitalization predict readmission in adolescents with eating disorders? J Adolesc Health 2014; 54(2): S78-9.
Reinke CE, Kelz RR, Zubizarreta JR, et al. Obesity and readmission in elderly surgical patients. Surgery 2012; 152(3): 355-62.
Zai AH, Ronquillo JG, Nieves R, Chueh HC, Kvedar JC, Jethwani K. Assessing hospital readmission risk factors in heart failure patients enrolled in a telemonitoring program. Int J Telemed Appl 2013; 2013: 305819.
Andersen KK, Olsen TS. The obesity paradox in stroke: Lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke 2013; 10(1): 99-104.
Manzano J-GM, Gadiraju S, Hiremath A, Lin HY, Farroni J, Halm J. Unplanned 30-Day readmissions in a general internal medicine hospitalist service at a comprehensive cancer center. J Oncol Pract 2015; 11(5): 410-5.
Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350(19): 1945-52.
Wolfe D, Yazdi F, Kanji S, et al. Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: A systematic review of systematic reviews. PLoS One 2018; 13(10): e0205426.
Min S, Zheng Q, Zhang B, et al. A meta-analysis of efficacy and adverse effects of lobaplatin and cisplatin in the treatment of malignant pleural effusion. Cancer 2019; 22(2): 90-8.
Suh WN, Kong KA, Han Y, et al. Risk factors associated with treatment refusal in lung cancer. Thorac Cancer 2017; 8(5): 443-50.